10
Loading video...

By Rachael O'Connor
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
There is a new option for breast cancer patients whose cancer has stopped responding to hormone therapy.
The Food and Drug Administration (FDA) has approved a daily pill, giredestrant, which should be taken in combination with the cancer drug everolimus.
Giredestrant latches onto estrogen receptors on cancer cells, blocking the hormone and making the receptors break down, while everolimus shuts down a separate pathway that makes cancer cells grow.
Read More on Health
The combo is for patients with advanced breast cancer that no longer responds to hormone therapy, and targets a specific type of cancer: ER-positive, HER-2 negative, that has spread to different parts of the body.
This type of cancer often develops ESR1 mutations, a change in the gene that stops hormone drug treatment from being effective, and seriously narrows the potential treatment options.
However, the FDA has now approved the new once-daily pill in patients whose tumors carry that mutation, and whose cancer came back or got worse despite hormone therapy.

...
Dr Isaac Garcia-Murillas of The Institute of Cancer Research in London, has told Newsweek the approval is important as it "validates an approach where understanding the molecular changes that drive resistance to hormone therapy can help guide treatment decisions for people with breast cancer."
"ESR1 mutations can emerge as breast cancers evolve during treatment, and we can detect these mutations using a simple blood test," Dr Garcia-Murillas explained. "Identifying patients whose tumors carry these mutations can help doctors select treatments that target the specific resistance mechanism driving their disease."
A blood test known as FoundationOne Liquid CDx has also been approved by the FDA, as it checks for a specific tumor DNA that would identify patients who could benefit from the giredestrant combination.
The approval of the combination of giredestrant and everolimus comes after a trial of 373 adults with that specific cancer, which had advanced after earlier treatment, and of which 207 had ESR1 mutations.
Every patient took everolimus, along with either giredestrant or a standard hormone therapy. Of the patients with the mutation, those taking giredestrant went a median of 10 months before the cancer worsened—compared to 5.5 months for those on standard hormone therapy.
The combined approach was also found to shrink tumors in 27 percent of cases, compared to 14 percent of those using standard hormone therapy.
Dr Garcia-Murillas told Newsweek that the clinical trial results were "encouraging," particularly because of the liquid biopsy blood test that can identify which patients "are most likely to benefit."
"However, it is still too early to know whether giredestrant will improve overall survival," he added.
The FDA, too, has warned that it is still too early to know whether the giredestrant combination helps people to live longer.
According to a report from Medical XPress, via an FDA release, some common adverse reactions in patients receiving the drug combination were inflammation in the mouth or lung tissue, rash, fatigue, diarrhea, musculoskeletal pain, and nausea. Some patients also experienced blood lab abnormalities.
The prescribing label reportedly includes warnings for slow heartbeat and adverse effects on a developing fetus during pregnancy.
Contact Newsweek editors on this story: Kara Dolman and Cristina Diciu.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines